BIOFINITY (COMFILCON A)
CooperVision, Inc. · Decision date Nov 19, 2008
What did the FDA approve?
FDA approved the BIOFINITY (comfilcon A) soft contact lens on November 19, 2008, under P080011. The approval covers sphere and aspheric lenses for myopia and hyperopia from -20.00 to +20.00 diopters, toric lenses adding astigmatic correction from -0.25 to -5.00 diopters, and multifocal lenses with add powers from +0.50 to +3.00 diopters. All are for aphakic and non-aphakic persons with non-diseased eyes.
The statement permits extended wear up to 6 nights and 7 days of continuous wear, with a recommendation that wearers first be evaluated on a daily wear schedule. Lenses may be prescribed for one-week disposable wear or frequent replacement with cleaning and disinfection. For frequent replacement, only a chemical disinfection system is specified. The statement reports the approved indications and wear schedules; it does not independently establish safety or clinical effectiveness.
FDA approval order statement
APPROVAL FOR THEBIOFINITY (COMFILCON A) SOFT CONTACT LENS. THIS DEVICE IS INDICATED FOR USE AS FOLLOWS:BIOFINITY (COMFILCON A) SPHERE AND ASPHERC SOFT CONTACT LENSES ARE INDICATED FOR THECORRECTION OF AMETROPIA (MYOPIA AND HYPEROPIA) IN APHAKIC AND NON-APHAKIC PERSONS WITH NON-DISEASED EYES IN POWERS FROM -20.00 TO +20.00 DIOPTERS. THE LENSES MAY BE WORN BYPERSONS WHO EXHIBIT ASTIGMATISM OF 2.00 DIOPTERS OR LESS THAT DOES NOT INTERFERE WITHVISUAL ACUITY.BIOFINITY (COMFILCON A) TORIC SOFT CONTACT LENSES ARE INDICATED FOR THE CORRECTION OFAMETROPIA (MYOPIA OR HYPEROPIA WITH ASTIGMATISM) IN APHAKIC AND NON-APHAKIC PERSONSWITH NON-DISEASED EYES IN POWERS FROM -20.00 TO +20.00 DIOPTERS AND ASTIGMATICCORRECTIONS FROM -0.25 TO -5.00 DIOPTERS.BIOFINITY (COMFILCON A) MULTIFOCAL SOFT CONTACT LENSES ARE INDICATED FOR THE CORRECTION OF REFRACTIVE AMETROPIA (MYOPIA AND HYPEROPIA) AND EMMETROPIA WITH PRESBYOPIA INAPHAKIC AND NON-APHAKIC PERSONS WITH NON-DISEASED EYES IN POWERS FROM -20.00 TO +20.00 DIOPTERS WITH ADD POWERS FROM +0.50 TO +3.00 DIOPTERS. THE LENSES MAY BE WORN BY PERSONS WHO EXHIBIT ASTIGMATISM OF 2.00 DIOPTERS OR LESS THAT DOES NOT INTERFERE WITH VISUAL ACUITY.BIOFINITY (COMFILCON A) CONTACT LENSES MAY BE PRESCRIBED FOR EXTENDED WEAR FOR UP TO 6 NIGHTS AND 7 DAYS OF CONTINUOUS WEAR. IT IS RECOMMENDED THAT THE CONTACT LENS WEARER BE FIRST EVALUATED ON A DAILY WEAR SCHEDULE PRIOR TO OVERNIGHT WEAR. THE LENSES MAY BEPRESCRIBED FOR EITHER ONE WEEK DISPOSABLE WEAR OR FOR FREQUENT REPLACEMENT WITH CLEANING,DISINFECTION AND SCHEDULED REPLACEMENT. WHEN PRESCRIBED FOR FREQUENT REPLACEMENT, THELENSES MUST BE CLEANED AND DISINFECTED USING A CHEMICAL DISINFECTION SYSTEM ONLY.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Ophthalmic
- Decision date
- Nov 19, 2008
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P080011
- Regulatory pathway
- Premarket approval application
- Applicant
- CooperVision, Inc.
- Product code
- LPM
- Decision code
- APPR
- Decision date
- Nov 19, 2008
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lenses, soft contact, extended wear.
- Applicant
- CooperVision, Inc.
- Product code
- LPM
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P080011 received
Application receipt date recorded by FDA.
P080011 · FDA decision
APPR
P080011/S204 · Related supplement
BIOFINITY (COMFILCON A)
Timeline entries are records held by MedtechLedger for P080011. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P080011
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
BIOFINITY (COMFILCON A)P080011/S204 | CooperVision, Inc. | PMA supplement | Sep 2, 2026 | FDA |
Explore the linked device profile
Other records with product code LPM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VISTAKON (senofilcon A) Brand Contact LensesP040045/S147 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 16, 2026 | FDA |
VISTAKON (SENOFILCON A) Brand Contact LensesP040045/S146 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 8, 2026 | FDA |
Bausch + Lomb Ultra (samfilcon A) Contact LensesP170035/S021 | Bausch and Lomb, Inc., | PMA supplement | Sep 14, 2026 | FDA |
| Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Sep 2, 2026 | FDA | |
| Bausch and Lomb, Inc., | PMA approval | Apr 30, 2018 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
CooperVision, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6101 Bollinger Canyon Rd., Suite 500, San Ramon, CA, 94583
Sources and methodology
- Original FDA record: P080011
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


